U.S. markets closed
  • S&P Futures

    3,752.75
    -4.00 (-0.11%)
     
  • Dow Futures

    29,973.00
    -9.00 (-0.03%)
     
  • Nasdaq Futures

    11,524.50
    -17.25 (-0.15%)
     
  • Russell 2000 Futures

    1,758.30
    +0.20 (+0.01%)
     
  • Crude Oil

    88.61
    +0.16 (+0.18%)
     
  • Gold

    1,720.50
    -0.30 (-0.02%)
     
  • Silver

    20.64
    -0.02 (-0.12%)
     
  • EUR/USD

    0.9794
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    3.8260
    +0.0670 (+1.78%)
     
  • Vix

    30.52
    +1.97 (+6.90%)
     
  • GBP/USD

    1.1145
    -0.0023 (-0.21%)
     
  • USD/JPY

    145.0480
    -0.0200 (-0.01%)
     
  • BTC-USD

    20,021.98
    -209.56 (-1.04%)
     
  • CMC Crypto 200

    455.61
    -7.52 (-1.62%)
     
  • FTSE 100

    6,997.27
    -55.35 (-0.78%)
     
  • Nikkei 225

    26,993.41
    -317.89 (-1.16%)
     

Viking Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference

·2 min read

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the Stifel 2021 Virtual Healthcare Conference. The conference, which will take place November 15-17, 2021, is being conducted with a virtual format.

Viking Therapeutics (PRNewsfoto/Viking Therapeutics, Inc.)
Viking Therapeutics (PRNewsfoto/Viking Therapeutics, Inc.)

Details for this presentation are as follows:

  • Stifel 2021 Virtual Healthcare Conference
    Conference Date: November 15-17, 2021
    Presentation Time/Date: 4:00 – 4:30 p.m. Eastern on Tuesday, November 16, 2021
    Format: Virtual conference

A webcast of the Stifel presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conferences.

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's second clinical candidate is VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated. The company is also developing a wholly-owned series of novel dual agonists of the GLP-1 and GIP receptors, for the potential treatment of metabolic disorders.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-stifel-2021-virtual-healthcare-conference-301420159.html

SOURCE Viking Therapeutics, Inc.